Weight-loss drugs in spotlight as pharma services firms rush to snap up business

Soaring demand for obesity drugs was in the spotlight at the world's largest trade show for the pharmaceutical services industry this week, as it fuels a boom for firms that fill and assemble the self-injection pens. A surge in sales of Novo Nordisk's drug Wegovy, which launched in the United States in mid-2021, has propelled the Danish drugmaker to become Europe's most valuable company. U.S. rival Eli Lilly has become the world's most valuable healthcare firm this year as demand for its diabetes drug Mounjaro surges ahead of approval for its use as a weight-loss treatment in the United States, expected by the end of this year.